Quince Therapeutics shareholders approve reverse stock split and authorized share increase

Quince Therapeutics, Inc.

Reverse stock split at 1-for-10 ratio approved (28,083,296 for vs 3,309,927 against).
Authorized common shares increased from 100M to 250M (27,159,134 for vs 3,776,348 against).
Directors June Bray, Christopher Senner, and Rajiv Patni elected with >85% of votes cast.
BDO USA ratified as independent auditor for FY2025 (30,015,571 for).
Advisory vote on executive compensation passed (16,590,485 for, 800,094 against).

item 5.07

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.